Abstract
The glutamate hypothesis of schizophrenia suggests that hypofunction of N-methyl-D-aspartate (NMDA) receptors may be critical for schizophrenic symptoms; therefore, pharmacological approaches that enhance NMDA function may be beneficial for the treatment of schizophrenia. Several lines of evidence indicate that NMDA and metabotropic glutamate (mGlu) 5 receptors are closely associated signaling partners and that a selective mGlu5 receptor agonist might provide a viable approach for increasing NMDA receptor function in the treatment of schizophrenia. The orthosteric binding sites across members of the mGlu receptor subtype for a particular endogenous ligand are often highly conserved, making it difficult to achieve high selectivity for the specific mGlu5 receptor. The advanced currents of drug discovery have developed multiple highly selective allosteric modulators of mGlu5 receptor. In the present review, we provide an update of the recent patents and development of positive allosteric modulators of the mGlu5 receptor and explore their therapeutic potential for schizophrenia.
Keywords: Metabotropic glutamate (mGlu) 5 receptor, G-protein-coupled receptor (GPCR), positive allosteric modulator, potentiator, schizophrenia
Recent Patents on CNS Drug Discovery (Discontinued)
Title: Recent Patents on Positive Allosteric Modulators of the Metabotropic Glutamate 5 Receptor as a Potential Treatment for Schizophrenia
Volume: 5 Issue: 1
Author(s): Kosuke Kanuma, Takeshi Aoki and Youichi Shimazaki
Affiliation:
Keywords: Metabotropic glutamate (mGlu) 5 receptor, G-protein-coupled receptor (GPCR), positive allosteric modulator, potentiator, schizophrenia
Abstract: The glutamate hypothesis of schizophrenia suggests that hypofunction of N-methyl-D-aspartate (NMDA) receptors may be critical for schizophrenic symptoms; therefore, pharmacological approaches that enhance NMDA function may be beneficial for the treatment of schizophrenia. Several lines of evidence indicate that NMDA and metabotropic glutamate (mGlu) 5 receptors are closely associated signaling partners and that a selective mGlu5 receptor agonist might provide a viable approach for increasing NMDA receptor function in the treatment of schizophrenia. The orthosteric binding sites across members of the mGlu receptor subtype for a particular endogenous ligand are often highly conserved, making it difficult to achieve high selectivity for the specific mGlu5 receptor. The advanced currents of drug discovery have developed multiple highly selective allosteric modulators of mGlu5 receptor. In the present review, we provide an update of the recent patents and development of positive allosteric modulators of the mGlu5 receptor and explore their therapeutic potential for schizophrenia.
Export Options
About this article
Cite this article as:
Kanuma Kosuke, Aoki Takeshi and Shimazaki Youichi, Recent Patents on Positive Allosteric Modulators of the Metabotropic Glutamate 5 Receptor as a Potential Treatment for Schizophrenia, Recent Patents on CNS Drug Discovery (Discontinued) 2010; 5 (1) . https://dx.doi.org/10.2174/157488910789753512
DOI https://dx.doi.org/10.2174/157488910789753512 |
Print ISSN 1574-8898 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3954 |
Related Books
Related Articles
-
Advances in Metabonomics on Infectious Diseases
Current Metabolomics Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Anti-Cancer Agents in Medicinal Chemistry Analysis of the Clinical Characteristics and Follow-up Study of Children with Cutaneous Polyarteritis Nodosa
Current Neurovascular Research Chondroitin Sulfate and Sulfur Containing Chondroprotective Agents: Is there a Basis for their Pharmacological Action?
Current Rheumatology Reviews The Cholesterol Transport Inhibitor U18666a Regulates Amyloid Precursor Protein Metabolism and Trafficking in N2aAPP “Swedish” Cells
Current Alzheimer Research Editorial: Are We in Need for Novel Therapeutics in Anxiety Disorders? (Thematic Issue: Non-Antidepressant Long Term Treatment of Anxiety Disorders)
Current Clinical Pharmacology Alzheimers Disease and Retinal Neurodegeneration
Current Alzheimer Research Synthesis, Anti-cancer Activity and Mechanism Study of 6-Mercapto-purine Derivatives
Letters in Drug Design & Discovery Herbal Medicine as an Alternative Treatment in Autism Spectrum Disorder: A Systematic Review
Current Drug Metabolism Heteroaromatization with 4-Phenyldiazenyl-1-naphthol. Part IV: Synthesis of Some New Heterocyclic Compounds with Potential Biological Activity
Current Organic Synthesis Recent Developments in Group I Metabotropic Glutamate Receptor Allosteric Modulators for the Treatment of Psychiatric and Neurological Disorders (2014-May 2015)
Current Topics in Medicinal Chemistry Transglutaminase Inhibition as a Possible Therapeutical Approach to Protect Cells from Death in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Acute Myocardial Infarction: High Risk Ventricular Tachyarrhythmias and Admission Glucose Level in Patients with and without Diabetes Mellitus
Current Diabetes Reviews Segmentation of Brain MRI for Detecting Alzheimer's Disease
Current Medical Imaging Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Development, Recent Achievements and Current Directions of Research into GABA Uptake Inhibitors
Current Medicinal Chemistry Integrins in Pulmonary Inflammatory Diseases
Current Pharmaceutical Design Nanoparticulate Mycophenolic Acid Eye Drops - Analytical Validation of a High Performance Liquid Chromatography Assay and Stability Studies
Pharmaceutical Nanotechnology Omega-3 Fatty Acids and Vulnerability to Addiction: Reviewing Preclinical and Clinical Evidence
Current Pharmaceutical Design Bromazepam Impairs Motor Response: An ERSP Study
CNS & Neurological Disorders - Drug Targets